Cabazitaxel is used for treating metastatic castration-resistant prostate cancer after prior treatment with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone. It was first introduced by Sanofi Aventis Us Inc in its drug Jevtana Kit on Jun 17, 2010. Another drug containing Cabazitaxel is Cabazitaxel. 8 different companies have introduced drugs containing Cabazitaxel.

Cabazitaxel Patents

Given below is the list of patents protecting Cabazitaxel, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Jevtana Kit	US8927592 (Pediatric)	Antitumoral use of cabazitaxel	Apr 27, 2031	Sanofi Aventis Us
Jevtana Kit	US10583110	Antitumoral use of cabazitaxel	Oct 27, 2030	Sanofi Aventis Us
Jevtana Kit	US10716777	Antitumoral use of cabazitaxel	Oct 27, 2030	Sanofi Aventis Us
Jevtana Kit	US8927592	Antitumoral use of cabazitaxel	Oct 27, 2030	Sanofi Aventis Us
Jevtana Kit	US7241907 (Pediatric)	Acetone solvate of dimethoxy docetaxel and its process of preparation	Jun 10, 2026	Sanofi Aventis Us
Jevtana Kit	US7241907	Acetone solvate of dimethoxy docetaxel and its process of preparation	Dec 10, 2025	Sanofi Aventis Us
Jevtana Kit	US5847170 (Pediatric)	Taxoids, their preparation and pharmaceutical compositions containing them	Sep 26, 2021 (Expired)	Sanofi Aventis Us
Jevtana Kit	US5847170	Taxoids, their preparation and pharmaceutical compositions containing them	Mar 26, 2016 (Expired)	Sanofi Aventis Us
Jevtana Kit	US6331635	Taxoids, their preparation and pharmaceutical compositions containing them	Mar 26, 2016 (Expired)	Sanofi Aventis Us
Jevtana Kit	US6372780	Methods of treating cell lines expressing multidrug resistance P-glycoprotein	Mar 26, 2016 (Expired)	Sanofi Aventis Us
Jevtana Kit	US6387946	Methods for treating pathological conditions of abnormal cell proliferation	Mar 26, 2016 (Expired)	Sanofi Aventis Us
Jevtana Kit	US5438072	Taxoid-based compositions	Nov 22, 2013 (Expired)	Sanofi Aventis Us
Jevtana Kit	US5698582	Compositions containing taxane derivatives	Jul 03, 2012 (Expired)	Sanofi Aventis Us

Add above patents to watchlist

Cabazitaxel's Family Patents

Full family tree

Cabazitaxel Generic API Manufacturers

Several generic applications have been filed for Cabazitaxel. The first generic version for Cabazitaxel was by Breckenridge Pharmaceutical Inc and was approved on Jun 23, 2022. And the latest generic version is by Mylan Laboratories Ltd and was approved on Jul 5, 2023.

Given below is the list of companies who have filed for Cabazitaxel generic, along with the locations of their manufacturing plants worldwide.